Immunic (NASDAQ:IMUX) Upgraded by StockNews.com to “Hold”

Immunic (NASDAQ:IMUX) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Separately, Brookline Capital Management reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Friday, April 5th.

Immunic Trading Down 7.1 %

Shares of NASDAQ IMUX traded down $0.09 during midday trading on Friday, reaching $1.18. The company’s stock had a trading volume of 365,394 shares, compared to its average volume of 876,208. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $3.11. The stock has a market capitalization of $106.12 million, a price-to-earnings ratio of -0.56 and a beta of 2.07. The stock has a 50 day simple moving average of $1.33 and a 200-day simple moving average of $1.27.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, February 22nd. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.03. As a group, equities analysts anticipate that Immunic will post -0.99 EPS for the current year.

Hedge Funds Weigh In On Immunic

Institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP increased its holdings in Immunic by 0.9% during the third quarter. RTW Investments LP now owns 4,335,255 shares of the company’s stock worth $6,373,000 after buying an additional 40,796 shares during the last quarter. Acadian Asset Management LLC increased its holdings in Immunic by 26.8% during the third quarter. Acadian Asset Management LLC now owns 757,250 shares of the company’s stock worth $1,111,000 after buying an additional 159,973 shares during the last quarter. Sweet Financial Partners LLC acquired a new position in Immunic during the fourth quarter worth $45,000. Innovis Asset Management LLC increased its holdings in Immunic by 46.3% during the third quarter. Innovis Asset Management LLC now owns 272,457 shares of the company’s stock worth $401,000 after buying an additional 86,217 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Immunic during the third quarter worth $77,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.